Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on innovative genetic therapies, has announced plans for an underwritten public offering of its common stock. The company will sell all shares in this proposed offering, with TD Cowen and BMO Capital Markets serving as joint book-running managers. Additionally, Prime Medicine intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The offering's completion is subject to market conditions and other factors, with final terms to be disclosed in a forthcoming prospectus supplement filed with the U.S. Securities and Exchange Commission $(SEC.UK)$.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503384-en) on July 30, 2025, and is solely responsible for the information contained therein.